Cited by 224HIV/AIDS Research and InterventionsHIV, Drug Use, Sexual RiskReproductive tract infections research

Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study.

Open access
Jenness, Samuel M, Weiss, Kevin M, Goodreau, Steven M, Gift, Thomas, Chesson, Harrell, Hoover, Karen W, Smith, Dawn K, Liu, Albert Y +2 more·2017·Clinical Infectious Diseases

Abstract

Background: Preexposure prophylaxis (PrEP) is highly effective for preventing human immunodeficiency virus (HIV) infection, but risk compensation (RC) in men who have sex with men (MSM) raises concerns about increased sexually transmitted infections (STIs). The Center for Disease Control and Prevention's (CDC's) PrEP guidelines recommend biannual STI screening, which may reduce incidence by treating STIs that would otherwise remain undiagnosed. We investigated these two counteracting phenomena. Methods: With a network-based mathematical model of HIV, Neisseria gonorrhoeae (NG), and Chlamydia trachomatis (CT) transmission dynamics among MSM in the United States, we simulated PrEP uptake following the prescription indications and HIV/STI screening recommendations in the CDC guidelines. Scenarios varied PrEP coverage (the proportion of MSM indicated for PrEP who received it), RC (a reduction in the per-act probability of condom use), and the STI screening interval. Results: In our reference scenario (40% coverage, 40% RC), 42% of NG and 40% of CT infections would be averted over the next decade. A doubling of RC would still result in net STI prevention relative to no PrEP. STIs declined because PrEP-related STI screening resulted in a 17% and 16% absolute increase in the treatment of asymptomatic and rectal STIs, respectively. Screening and timely treatment at quarterly vs biannual intervals would reduce STI incidence an additional 50%. Conclusions: Implementation of the CDC PrEP guidelines while scaling up PrEP coverage could result in a significant decline in STI incidence among MSM. Our study highlights the design of PrEP not only as antiretroviral medication but as combination HIV/STI prevention incorporating STI screening.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/cix439

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In an MSM transmission model that explored the impact of HIV PrEP use on STI prevalence, quarterly chlamydia and gonorrhea screening was associated with an 83% reduction in incidence.

    “In an MSM transmission model that explored the impact of HIV PrEP use on STI prevalence, quarterly chlamydia and gonorrhea screening was associated with an 83% reduction in incidence (205).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [205]

  • Studies have reported that MSM taking PrEP have high rates of STIs, and frequent screening is warranted.

    “Studies have reported that MSM taking PrEP have high rates of STIs, and frequent screening is warranted (204–206).”

    From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [205]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. McCormack S. Sexually transmitted infection control in the era of PrEP. In: Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2016.
  2. Molina J, Charreau I, Spire B, et al. Efficacy of on demand PrEP with TDF-FTC in the ANRS IPERGAY open-label extension study. In: 21st International AIDS Conference (AIDS 2016). Durban, South Africa: 2016.
  3. Cohen SE, Vittinghoff E, Philip SS, et al. Quarterly STI screening optimizes STI detection among PrEP users in the demo project. Conference on Retroviruses and Opportunistic Infections (CROI). Boston, 2016.
  4. Goodreau SM, Carnegie NB, Vittinghoff E, et al. What drives the US and Peruvian HIV epidemics in men who have sex with men (MSM)? PLoS One 2012; 7:e50522.
  5. Low N, Heijne JC, Herzog SA, Althaus CL. Reinfection by untreated partners of people treated for Chlamydia trachomatis and Neisseria gonorrhoeae: mathemati- cal modelling study. Sex Transm Infect 2014; 90:254-6.

Cited by

Sorted by citations

Authors
Jenness, S. M., Weiss, K. M., Goodreau, S. M., Gift, T., Chesson, H., Hoover, K. W., Smith, D. K., Liu, A. Y., Sullivan, P. S., & Rosenberg, E. S.
Affiliations
  • Emory University (US)
  • University of Washington (US)
  • Division of STD Prevention, and
  • Centers for Disease Control and Prevention (US)
  • San Francisco Department of Public Health (US)
Corresponding author
Jenness, Samuel M
Venue
Clinical Infectious Diseases
Published
2017-05-13
Volume
65
Issue
5
Pages
712-718
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2612576926
Cited by
224
References
38
Citations by year
2026: 7 · 2025: 13 · 2024: 20 · 2023: 30 · 2022: 20 · 2021: 21 · 2020: 32 · 2019: 43 · 2018: 31 · 2017: 7
FWCI
23.79
Type
journal article
Language
en
Open access
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (R21 MH112449, R21 HD075662)
  • CDC (U38 PS004646)
  • University of Washington (P30 AI027757)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
HIV pre-exposure prophylaxis, men who have sex with men, gonorrhea, chlamydia, risk compensation, STI screening, condom use, STI incidence, PrEP coverage, HIV transmission dynamics
MeSH terms
Chlamydia Infections, Gonorrhea, Humans, Male, Models, Statistical, Cohort Studies, HIV Infections, Homosexuality, Male, Pre-Exposure Prophylaxis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review